UK Markets closed

Global Cancer Diagnostics Partnering Deal Terms and Agreements 2015-2022: Access to Over 1000 Deal Records - Company A-Z, Stage of Development, Deal Type, Therapy Focus, and Technology Type

·6-min read
Company Logo
Company Logo

Dublin, June 13, 2022 (GLOBE NEWSWIRE) -- The "Global Cancer Diagnostics Partnering Terms and Agreements 2015-2022" report has been added to's offering.

The Global Cancer Diagnostics Partnering Terms and Agreements 2015-2022 report provides comprehensive access to available deals and contract documents for over 1000 Cancer Diagnostics deals.

The report takes the reader through a comprehensive review Cancer Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Cancer Diagnostics partnering deals.

The report presents financial deal term values for Cancer Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Cancer Diagnostics partnering field; both the leading deal values and most active Cancer Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 1000 online deal records of actual Cancer Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

A comprehensive series of appendices is provided organized by Cancer Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Cancer Diagnostics technologies and products.

Key benefits

Global Cancer Diagnostics Partnering Terms and Agreements 2015-2022 provides the reader with the following key benefits:

  • In-depth understanding of Cancer Diagnostics deal trends since 2015

  • Access to headline, upfront, milestone and royalty data

  • Detailed access to actual Cancer Diagnostics contracts entered into by leading biopharma companies

  • Identify most active Cancer Diagnostics dealmakers since 2015

  • Insight into terms included in a Cancer Diagnostics partnering agreement, with real world examples

  • Understand the key deal terms companies have agreed in previous deals

  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

In Global Cancer Diagnostics Partnering Terms and Agreements 2015-2022, the available deals are listed by:

  • Company A-Z

  • Headline value

  • Stage of development at signing

  • Deal component type

  • Specific therapy target

  • Technology type

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?

  • What is actually granted by the agreement to the partner company?

  • What exclusivity is granted?

  • What is the payment structure for the deal?

  • How are sales and payments audited?

  • What is the deal term?

  • How are the key terms of the agreement defined?

  • How are IPRs handled and owned?

  • Who is responsible for commercialization?

  • Who is responsible for development, supply, and manufacture?

  • How is confidentiality and publication managed?

  • How are disputes to be resolved?

  • Under what conditions can the deal be terminated?

  • What happens when there is a change of ownership?

  • What sublicensing and subcontracting provisions have been agreed?

  • Which boilerplate clauses does the company insist upon?

  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

  • Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Cancer Diagnostics dealmaking
2.1. Introduction
2.2. Cancer Diagnostics partnering over the years
2.3. Most active Cancer Diagnostics dealmakers
2.4. Cancer Diagnostics partnering by deal type
2.5. Cancer Diagnostics partnering by therapy area
2.6. Deal terms for Cancer Diagnostics partnering
2.6.1 Cancer Diagnostics partnering headline values
2.6.2 Cancer Diagnostics deal upfront payments
2.6.3 Cancer Diagnostics deal milestone payments
2.6.4 Cancer Diagnostics royalty rates

Chapter 3 - Leading Cancer Diagnostics deals
3.1. Introduction
3.2. Top Cancer Diagnostics deals by value

Chapter 4 - Most active Cancer Diagnostics dealmakers
4.1. Introduction
4.2. Most active Cancer Diagnostics dealmakers
4.3. Most active Cancer Diagnostics partnering company profiles

Chapter 5 - Cancer Diagnostics contracts dealmaking directory
5.1. Introduction
5.2. Cancer Diagnostics contracts dealmaking directory

Chapter 6 - Cancer Diagnostics dealmaking by technology type

Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendix 1 - Cancer Diagnostics deals by company A-Z
Appendix 2 - Cancer Diagnostics deals by stage of development

  • Discovery

  • Preclinical

  • Phase I

  • Phase II

  • Phase III

  • Regulatory

  • Marketed

  • Formulation

Appendix 3 - Cancer Diagnostics deals by deal type

  • Asset purchase

  • Assignment

  • Bigpharma outlicensing

  • Co-development

  • Collaborative R&D

  • Co-market

  • Co-promotion


  • Cross-licensing

  • Development

  • Distribution

  • Equity purchase

  • Evaluation

  • Grant

  • Joint venture

  • Licensing

  • Litigation

  • Manufacturing

  • Marketing

  • Material transfer

  • Option

  • Promotion

  • Research

  • Settlement

  • Spin out

  • Sub-license

  • Supply

  • Technology transfer

  • Termination

  • Warranty

Appendix 4 - Cancer Diagnostics deals by therapy area
Appendix 5 -Deal type definitions
Appendix 6 - Further reading on dealmaking

Table of figures
Figure 1: Cancer Diagnostics partnering since 2015
Figure 2: Active Cancer Diagnostics dealmaking activity since 2015
Figure 3: Cancer Diagnostics partnering by deal type since 2015
Figure 4: Cancer Diagnostics partnering by disease type since 2015
Figure 5: Cancer Diagnostics deals with a headline value
Figure 6: Cancer Diagnostics deals with an upfront value
Figure 7: Cancer Diagnostics deals with a milestone value
Figure 8: Cancer Diagnostics deals with a royalty rate value
Figure 9: Top Cancer Diagnostics deals by value since 2015
Figure 10: Most active Cancer Diagnostics dealmakers since 2015

Companies Mentioned

  • Aetna

  • Amgen

  • Angle

  • Axela

  • Bayer

  • BL&H

  • Ceres

  • COTA


  • Cypre

  • D-Eye

  • Dako

  • Dell

  • Eigen

  • Falco

  • Fscan

  • GIMDx

  • Glide

  • Grail

  • IBM

  • iCAD

  • IPMD

  • Item

  • KEW

  • Lab21

  • Mavig

  • Medx

  • MIODx

  • NASA

  • Ochin

  • Orot+

  • RAW

  • Roche

  • Sebia

  • Seer

  • TaiRx

  • Take2

  • Telik

  • UPMC

  • ZoBio

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood, Senior Press Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting